[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614448":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":36,"locations":47,"responsibleParty":62,"collaborators":25,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":25,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":25,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":88,"whyStopped":25,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"nalbuphine group","ACTIVE_COMPARATOR","• Patients in group N (Nalbuphine group) will receive 29 mL of 0.5% bupivacaine + 1 mL (containing 10 mg nalbuphine)",[13],"Drug: Nalbuphine",{"label":15,"type":10,"description":16,"interventionNames":17},"Dexmedetomidine group","• Patients in group D (Dexmedetomidine group) will receive 29 mL of 0.5% bupivacaine + 1mL (containing 75 µg dexmedetomidine",[18],"Drug: Dexmedetomidine",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Nalbuphine","Nalbuphine will be added to .5% bupivacaine as an adjuvant in infraclavicular nerve block",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Dexmedetomidine","Dexmedetomidine will be added to .5% bupivacaine as an adjuvant in infraclavicular nerve block",[15],[31],"precedex",[33],{"name":34,"affiliation":5,"role":35},"Momen mostafa meki, Dr","PRINCIPAL_INVESTIGATOR",[37,43],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Momen mostafa meki, dr","CONTACT","01223344886","088","moamen.meki@med.aun.edu.eg",{"name":44,"role":39,"phone":45,"phoneExt":41,"email":46},"Hossam El-din Gamal Fakhry, Dr.","01026269773","hossam.hg@aun.edu.eg",[48],{"facility":49,"status":25,"city":50,"state":51,"zip":25,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Faculty of medicine Assiut University, Assiut,","Asyut","Asyut Governorate","Egypt","EG",{"type":55,"coordinates":56},"Point",[57,58],31.18368,27.18096,{"lat":58,"lon":57},[61],{"name":34,"role":39,"phone":40,"phoneExt":41,"email":42},{"type":35,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Mo'men mostafa youssef","Lecturer of Anesthesia and icu","100614448","phase-1-ultrasound-guided-infraclvicular-block-using-dexmedetomidine-versus-nalbuphine-as-adjuvants-to-bupivacaine-in-upper-limb-orthopedic-surgery-100614448",false,"NCT07279727","Ultrasound-Guided Infraclvicular Block Using Dexmedetomidine Versus Nalbuphine as Adjuvants to Bupivacaine in Upper Limb Orthopedic Surgery","Ultrasound-Guided Infraclvicular Block Using Dexmedetomidine Versus Nalbuphine as Adjuvants to Bupivacaine in Upper Limb Orthopedic Surgery: A Prospective, Randomized, Double-Blind Controlled Study","Inclusion Criteria:\n\nAdults aged 18-65 years ASA I-II (American Society of Anesthesiologists physical status classification) Scheduled for elective upper limb orthopedic surgeries Able to provide informed consent to participate in the study\n\nExclusion Criteria:\n\nRefusal to participate in the study Pregnancy Allergy to any study drug(s) Neurological disease (e.g., neuropathies, central nervous system disorders) Coagulopathy or active bleeding disorders Severe systemic diseases (e.g., uncontrolled cardiovascular, renal, or liver disease) Opioid abuse or history of substance use disorder","ALL","18 Years","65 Years",{"count":76,"type":77},66,"ESTIMATED","INTERVENTIONAL",[80],"PHASE1","this study is designed to evaluate and compare the efficacy of dexmedetomidine and nalbuphine as adjuvants to 0.5% bupivacaine in ultrasound-guided infraclavicular brachial plexus block for patients undergoing elective upper limb orthopedic surgeries on the duration of analgesia.",[83],"Regional Anaesthesia",[22,27,85,86,87],"Duration of analgesia","Bupivacaine","Infraclavicular block","NOT_YET_RECRUITING","2025-12-10",{"date":91,"type":92},"2025-12-12","ACTUAL",{"date":94,"type":77},"2026-01-01",{"date":96,"type":77},"2027-04-01",{"name":5,"class":6},1]